The market size of 100 billion, organ regeneration, regeneration materials, stem cells ... regenerative medicine blossoms

Organs can regenerate, and the human body can grow old ... Regenerative medicine has made the plot that appeared in science fiction films in the past to become a reality.

Regeneration medicine refers to the use of the theoretical and engineering of biology and engineering to create tissues and organs that are lost or functional damage to promote the self -repair and regeneration of the body, so that it has the structure and function of normal tissue and organs. Congenital genetic defects, neurological diseases, rare diseases and other diseases have brought new hope, and they are expected to completely cure certain diseases.

According to statistics from the United States Renewal Medicine Alliance, the financing amount in the field of regeneration medicine in 2021 is as high as US $ 23.1 billion, and 1308 companies worldwide are actively developing the field of recycled medicine. In addition, according to Statista statistics, the global renewable medical market in 2021 is about 16.9 billion U.S. dollars, and it is expected to reach US $ 95.5 billion in 2030 and 21.22%of CAGR.

The concept of regeneration medicine is wide and there are many forms. At present, the strategy that regeneration medicine is exploring includes: replacing the damaged tissue by transplanting cell suspension or polymers; the implantation of biological artificial tissues or organs that can replace natural tissues in laboratory; Part of the regeneration induction.

At present, subdivisions such as stem cells, biological regeneration materials, and organ regeneration are already potential tracks in the medical field, with a large number of enterprises and rapid research progress.

From repairing to organ regeneration, advanced medicine

Organizational defect repair and regeneration are one of the major topics in the field of modern medicine. The medical community has extensive and in -depth exploration in regeneration medicine.

The main path of regeneration medicine includes drug therapy, which promotes diseased cells through drugs and produces more signal factors required by the body, such as the growth factor of FGF protein growth factor to promote the production of the brain Tissue that repair trauma, such as cell therapy in orthopedic application, transplantation through autologous cartilage cells to repair cartilage trauma; gene therapy, through genetic modification and gene editing, uses animal organs to be used by people. Existing cases have obtained clinical clinical clinical in 2019. Entering human tests; biomass combines cell therapy, combines growth factors through biomass materials, and combined with stem cells to build a living tissue in vitro -peripheral nerves, which is applied to tissue repair.

In addition, cutting -edge research directions such as exosoma, synthetic biology, mRNA, and microcrea are gradually being applied to the field of regeneration medicine.

Regenerative Medical Technology Path

In this article, the arterial network divides recycled medicine into three major sections: biological regeneration materials, stem cell repair, and organ regeneration. Bio -regeneration materials, used for bone repair, oral repair, medical beauty, etc.; Stem cell repair, based on stem cell technology, repair the original unable to renewable tissue and organs; regeneration organs, based on stem cells, biological 3D printing and other technologies, develop artificial tissue organs, and Including artificial blood vessels, artificial kidneys, artificial pancreas, etc.

■ Bio -regeneration materials: There are many products on the market, and the import substitution effects appear

Bio -regenerative materials are different from traditional biomedical materials. They use organizational engineering technology to fix, sterilize and eliminate antigenicity by maintaining the original structure of the tissue, as well as disassembling the original configuration, rebuilding new physical forms, etc. Special processing and processing new high -tech materials.

Bio -regenerative materials have excellent organizational induction, implant biological regeneration materials into the human body, and can induce defect tissue and organs for regeneration and repair. Repair, soft tissue repair, joint cartilage repair, blood vessels and duct coatings, medical beauty, etc.

Bio -regeneration materials are the earlier and faster trapes in the field of regeneration medicine. According to the research of Fhstrishalvin, with the dual support of funds and policies, the ability to independent innovation in Chinese biological regeneration materials has significantly enhanced, and biological regeneration products such as ductilums, ductilums, and oral repair membranes have been successfully developed. The market share has increased year by year. Among them, in the field of hard meningers, the market share of local brands has reached more than 50%, and import substitutional benefits have gradually begun to appear.

At present, mainstream biological regeneration materials include clustering lactic acid and silk protein. Among them, Li Xin Science is based on new materials such as polystumin, and has formed three lines of absorbing internal fixed products, bone filling products, and medical beauty absorption polymer products. The performance of artificial bone products with excellent shaping, anti -liquid collapse, and high -efficiency bone -induced regeneration performance fills global product gaps.

Some new biological regenerative materials enterprises

The three companies of Zhenghai Biological, Guanhao Biology, and Mippu Medical have successfully listed.

Zhenghai Biological Soft Tased Repair Series Products Valbled Repair Membrane, Absorbing Hard Cerebral (Condition) Film, Skin Repair Megons, etc. have been used in dental department, head and neck surgery, neurosurgery and other fields; hard tissue repair product bone repair materials are guidance Functional bracket materials for bone injury repair. In the first half of 2022, Zhenghai Bio achieved revenue of 231 million yuan, an increase of 15.15%year -on -year, and net profit attributable to the mother was 104 million yuan, an increase of 28.36%year -on -year, and the non -net profit was 103 million yuan, an increase of 30.41%year -on -year.

The products that have been listed on Guanhao Biological include biological duct (spine) film supplement, B -type ductal supplementary tablets, thoracic surgical repair membrane (B/P), sterile biosure film, and Erico breast supplementary tablets Youdeci -deleted cells, and artificial crystal products represented by Zhuhai Xiangle, are applied to neurosurgery, thoracic surgery, ophthalmology, dermatology, orthopedics, plastic surgery and so on. In the first half of 2022, the company's revenue was 203 million yuan, and the net profit loss was 244 million yuan, a decrease of 22.68%year -on -year. Mippin is the only company in the field of domestic neurosurgery at the same time that has artificial hard brain (spine) film supplement, craniotomy repair products, and absorbing regenerative oxidized cellulose hemostatic products. In the first half of 2022, the company realized operating income of 950.249 million yuan, an increase of 38.24%over the same period last year; the net profit attributable to shareholders of listed companies was 2,240,600 yuan, an increase of 1.52%over the same period last year.

Next, biological regeneration materials will continue to innovate, and the product types will be further enriched. It is worth noting that biological regeneration materials provide a renewable environment for human tissues, and still need to rely on the human body's renewable capabilities. For non -renewable tissues and organs such as corneal, nerve cells, and hearts, more technologies such as stem cells are needed to repair and regenerate.

■ Stem cell repair: universal cells, can be differentiated into specific types of cells, repair damaged tissue organs

Stem cells are a class of cells with the ability to update and differentiate the differentiation of self -renewal and proliferation differentiation in the embryo, fetus or adults. They can produce the same sub -cells that are exactly the same as their genotypes and themselves. The specialized cells of the organs can also be differentiated into ancestral cells, also known as "universal cells".

Stem cells can be induced into specific types of cells, such as myocardial cells, blood cells, or nerve cells, for repair and regeneration of human lesions and damaged tissues. Stem cell therapy is the core of regenerative medical research in recent years. "Special Management measures for foreign investment access (negative list) (2019 edition) pointed out that the human stem cell field clearly prohibits foreign investment technology development and application, which shows that stem cell technology is the focus of competition in various countries.

At present, domestic enterprises have a wide range of layouts on stem cell repair and regeneration tracks.

Companies of some layout of stem cell repair business

According to statistics, the fields of application diseases currently based on stem cell repair include spinal cord injury, type I diabetes, Parkinson disease, Alzheimer's disease, heart disease, stroke, burns, cancer and osteoarthritis.

Among them, the bloody creature is the third company in the world after Japan's Megakaryon and Plateletbio in the United States. China's first company focusing on platelets to regenerate in vitro, solving cancer, liver disease, critical illness, blood disease and other diseases. And the development of innovative drugs related to various platelet abnormal diseases.

Elp Regenerative Medicine uses IPSC technology for cell therapy and production. IPSC technology therapy that treats severity heart failure has entered multiple authoritative centers across the country and conducted large -scale randomly controlled clinical trials of the human body. On December 17, 2021, the IPSC source myocyte injection of the person independently developed by Nanjing Elp Regenerative Medicine Technology Co., Ltd. was accepted by the drug review center.

Shizawa creatures are committed to providing large -scale, low -cost stem cell therapy plans for major diseases such as Parkinson's disease and other major diseases. Cell -alternative treatment methods for alternative functional injury or degeneration can solve major human diseases.

However, stem cells are currently limited to the repair of tissue and organs, and have not yet achieved organ regeneration in the real sense.

■ Regenerative organs: "Pyramid tip" of artificial organs, fewer layout companies, and far industrialization

Regenerative organs are considered to be the ultimate solution to crack the pain points of traditional organ transplantation.

Organic organs defects and functional defects caused by trauma, disease and aging are very common. Organ transplantation is the first choice for treatment. However, there are two major problems in organ transplantation. One is the severe shortage of exotic transplants. The data shows that the number of patients transplants in my country continued to increase. In 2020, about 300,000 people waiting instruments transplanted, but the number of organs for transplantation in China is less than 20,000. indivual. The second is the problem of rejection. After transplantation, a large number of immunosuppressive drugs need to be taken. For example, after kidney transplantation, patients may take 20 or thirty various anti-excretion drugs every day. And prone to infection.

The concept of regeneration organs is different from artificial organs. Artificial organs include mechanical artificial organs, such as high -molecular materials or alloys such as high -molecular materials or alloys. They use battery as the power and semi -mechanical and semi -biological artificial organs. Essence

Regenerative organs refer to the use of cells to create artificial organs with biological activity. They do not require external power such as batteries. The use cycle is long and will not cause rejection after transplanting organs. It is the "pyramid tip" of artificial organs.

At present, most of the regenerative medical companies focus on the repair of organizations and organs, and there are few morning stars in the layout of recycled organs. The arterial network statistics have 6 domestic enterprises that are currently in the layout of recycled organs. The layout directions include artificial blood vessels, artificial pancreas, artificial kidneys, and artificial liver. Regenerative organs -related enterprises

Huawei Hengyuan and Nuo and Noord cooperate to develop a diabetic immune exemption from artificial pancreatic products-diabetic islet protection carrier#ISLETSC-1, which is currently in the stage of clinical research. Under the traditional insulin treatment, patients need to inject insulin daily and monitor blood sugar from time to time. Daily life is completely dominated by insulin, while artificial pancreatic cells transplant immune exclusion reactions. Diabetic immune exemptions are exempted from artificial pancreas, allowing islet transplant cells to survive for a long time in the patient's body, and continuously produce insulin to regulate blood sugar.

Huayuan Regenerative Medicine uses stem cells and tissue engineering technology to create human -produced biological synthetic organs suitable for human transplantation to treat end -stage organ diseases and transplantation of biological composite artificial pancreas, in vitro artificial kidneys, and biological synthesis can be implanted with artificial kidney.

Zhixinhao is focusing on the internal and external body of the human tissue. The primary pipeline is to transplant the recycled islets that can be used to treat diabetes. Thousands of practice clinically proved that the islet tissue donated by the deceased through vascular transplants into the liver, and nearly 70%of diabetes subjects can completely completely separate insulin, showing the huge potential of islet transplantation root treatment to treat insulin dependent diabetes; however The severe scarce of the body and the need to take immunosuppressive agents for life have greatly restricted the promotion and inclusiveness of this therapy. Zhixin Hao is using stem cells to re -recurring with in vitro to solve the bottleneck of islet transplantation.

In general, the regeneration organs are still in the early stage of domestic and global. The pipelines of domestic enterprises are generally in the clinical stage, and they have not achieved large -scale and commercialization. They also need to go through long -term development.

Early financing, and regeneration medicine is still in a very early stage

According to the statistics of the arterial network, 70 financing incidents occurred in the field of regeneration medicine in my country, with a total financing of more than 1.5 billion yuan.

Regenerative medical enterprise financing situation

The financing situation in the field of regeneration medicine is more considerable, showing an overall rise, which has attracted many top investment institutions in the medical field. Ru Lili Asia Fund and Sequoia Seed Fund invested in Shizawa Bio and Sequoia China invested in Nopp regeneration and bloody biology.

my country's renewable medical enterprise is located in financing rounds

From the perspective of the financing round of enterprises, the company's financing rounds are too early. There are 11 in the round A financing stage. There are 5 angel round financing stage, and 4 of the IPO/New Third Board. Judging from the business of the enterprise, the directions of each subdivision have received high attention of capital. At present, the IPO companies are the subdivisions of biological regeneration materials. Stem cell restoration and regeneration organs have started late, and the enterprises are in the early stages.

To be sure, there is still great potential in the field of regeneration medicine without eruption.

From the perspective of the coverage scene, the key application scenarios of recycled medicine such as medical beauty, orthopedics, oral cavity, cardiovascular disease, and nerves have many companies financing. It can be seen that regenerative medicine has received widespread and in -depth attention of capital. In the future, these key scenarios will still have room for further growth.

Among them, the size of the Chinese medical beauty market continued to increase from 2018 to 2021, about 227.4 billion yuan in 2021, an increase of 15.10%over 2020. According to the "White Paper of the more beautiful 2021 medical beauty industry" released by the more beautiful app, the size of the Chinese medical beauty market in 2022 will still maintain a high -speed growth, the growth rate exceeds 16%, and the market size may reach 264.3 billion yuan. Medical beauty injection is entering the "regeneration era" from the filling era. Three domestic medical products based on recycled materials have been approved to be listed. East China Pharmaceutical's "Yiyan Shi" has signed a cooperation hospital for more than 500 in one year.

In the orthopedic market, in recent years, the demand for clinical surgery related to aged ages in recent years has continued to rise. The size of my country's orthopedic implant market has increased from 11.7 billion yuan in 2013 to 36 billion yuan in 2020, with a compound annual growth rate of 17.14%. The world's second largest orthopedic implant market. In the context of the incidence of orthopedics, the application of orthopedic recycled medical products will become wider and wider.

From the perspective of policy, the global aging continues to intensify, and the traditional treatment model is difficult to solve many problems such as tissue and organs defect repair and regeneration. Regenerative medicine can achieve functional living cells, tissues or organs through functional. Repair and replace the organization, organs, or functions caused by major strategic significance and is the general direction of long -term encouragement of policies.

Regenerative medicine related policies sort out

However, it is not avoided that the development of China's regeneration medicine field is still extremely early. Products such as bone repair, regenerative medical beauty, oral repair, etc. have been commercialized, and high -tech barriers such as regeneration organs are still at the scientific research level. It is reported that regenerating kidneys and regenerative hearts have no products globally. Two laboratory enters phase II clinical, 5-6 enters phase I clinical.

In the future, the further development of China Regenerative Medicine will also depend on the continuous breakthroughs in policy supervision, capital, product research and development, and upstream and downstream collaboration.

- END -